R-Tech Ueno: Announcement on Completion of the Phase I Single-Dose Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096
TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ: 4573) We are pleased to announce that the phase I single-dose clinical trial for the new molecular entity RTU-1096 has been completed. RTU-1096 is a vascular adhesion protein-1 (VAP-1) inhibitor having anti-inflammatory and immunomodulatory effects. The descriptions of the trial result are as follows: The company has been developing an anti-inflammatory drug with a new mechanism of action based on VAP-1 inhibitory effect. We are currently conducting
